Matt Duncton

Dr. Matt Duncton has over 20 years of experience in medicinal chemistry with a career working in oncology, immunology, anti-infectives and neuroscience therapeutic areas at companies such as Merck, Vernalis, OSI Pharmaceuticals, ImClone Systems, Renovis, and Rigel Pharmaceuticals. Since 2016, Matt has served as an independent consultant in medicinal chemistry working with small biopharmaceutical organizations, Venture Capital groups and academia. Matt is an author/inventor on more than 90 papers and patents and his work has led to projects advancing in to human clinical trials, such as ARX-1796 (recently licensed to Pfizer), NFX-179 (currently, Phase II), RN-5327 (TRPV1 antagonist; Phase I), and a host of other IND candidates.